Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

We are thrilled to welcome Jay to the Agios Board of Directors,” said Brian Goff, Chief Executive Officer, Agios. “His deep scientific insight, extensive regulatory expertise, and strategic business ...

Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...